Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 4Endocrine 4Thoracic 3Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 60Lung Neoplasms 38Melanoma 22Ovarian Neoplasms 20Breast Neoplasms 18Mesothelioma, Malignant 13Colorectal Neoplasms 13Pancreatic Neoplasms 12Neoplasm Metastasis 12Small Cell Lung Carcinoma 11Triple Negative Breast Neoplasms 10Carcinoma, Renal Cell 10Neoplasms 9Mesothelioma 9Stomach Neoplasms 8Sarcoma 8Thymoma 7Carcinoma, Hepatocellular 7Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Merkel Cell 6Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Adenocarcinoma of Lung 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Sarcoma, Synovial 4Multiple Myeloma 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Cyclophosphamide × Thoracic × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT03412877 2026-05-29

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡